Evidence map›Paper›PMID 37625197›Full record

ArticleESMO open2023

Corrigendum to 'Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up': [ESMO Open 7(6):100602, December 2022].

C van Herpen, V Vander Poorten, A Skalova, C Terhaard, R Maroldi, A van Engen, B Baujat, L D Locati, A D Jensen, L Smeele and 7 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Limitations of FNAC in detecting parotid malignancies: insights from a surgical cohort using the updated Milan System.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 8 countries.

C van HerpenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; Multidisciplinary Salivary Gland Society, Geneva, Switzerland.
V Vander PoortenMultidisciplinary Salivary Gland Society, Geneva, Switzerland; Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
A SkalovaMultidisciplinary Salivary Gland Society, Geneva, Switzerland; Department of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic.
C TerhaardMultidisciplinary Salivary Gland Society, Geneva, Switzerland; Department of Radiotherapy, University Medical Center, Utrecht, The Netherlands.
R MaroldiDepartment of Radiology, ASST Spedali Civili-Bresciad University of Brescia, Brescia, Italy.
A van EngenDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
B BaujatDepartment of Otorhinolaryngology, Head and Neck Surgery, Sorbonne Université Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France.
L D LocatiHead and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
A D JensenFaculty of Medicine, Philipps-University Marburg, Marburg; Department of Radiation Oncology, University Hospitals Gießen and Marburg (UKGM) Ltd, Gießen, Germany.
L SmeeleDepartment of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek Ziekenhuis & Amsterdam UMC, Amsterdam.
J HardilloDepartment of Otorhinolaryngology, Head and Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
V Costes MartineauDepartment of Pathology, CHU Montpellier, Montpellier, France.
A TramaEvaluative Epidemiology, Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy.
E KinlochSalivary Gland Cancer UK, London, UK.
C EvenHead and Neck Department, Gustave Roussy, Paris; French Network for Rare Head and Neck Cancers, Paris, France.
J-P MachielsService d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels; Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Fondazione IRCCS Istituto Nazionale dei Tumori · ITRadboud University Nijmegen · NLAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITCentre Hospitalier Universitaire de Montpellier · FRCharles University · CZCliniques Universitaires Saint-Luc · BEErasmus MC · NLInstitut Gustave Roussy · FRInternational Union for Conservation of Nature · CHPhilipps University of Marburg · DEProstate Cancer UK · GBSorbonne Université · FRThe Netherlands Cancer Institute · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37625197
PMCPMC10470209
OpenAlexW4386112395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.